To meet growing demands of advanced therapy manufacturing, production architectures must shift towards agile, efficient manufacturing systems. By integrating robotic gloveless isolator (RGI) technology into bioproduction, manufacturers can meet the needs of plasmid DNA, viral vector, and mRNA-based medicines while maintaining compliance with stringent regulatory standards.
Read the full article by Peter Boman (NorthX Biologics), and Zach Hartman (Cytiva), in Cell & Gene Therapy Insights here.